Antiviral Chemotherapy 5

New Directions for Clinical Application and Research

John Mills, Paul A. Volberding, Lawrence Corey (Herausgeber)

Buch | Softcover

271 Seiten

2012 | Softcover reprint of the original 1st ed. 1999
Springer-Verlag New York Inc.
978-1-4613-7150-2 (ISBN)

Artikel merken

Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in cubation period of active HIV infection, when the infection is clinically latent, is now un derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.

1. Overview of HBV Therapy.- 2. Lamivudine Therapy of Chronic Hepatitis B.- 3. Famciclovir Update: Chronic Hepatitis B.- 4. Current Status of Antiviral Therapy for Chronic Hepatitis C.- 5. Prevention and Treatment of Respiratory Syncytial Virus Infections.- 6. Update on Influenza and Rhinovirus Infections.- 7. Pleconaril: A Broad Spectrum Antipicornaviral Agent.- 8. Management of CMV Infections in HIV-Infected Patients.- 9. Management of Cytomegalovirus Infections in Blood and Marrow Transplant Recipients.- 10. Cidofovir: Review of Current and Potential Clinical Uses.- 11. Oral Ganciclovir.- 12. Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease.- 13. Famciclovir/Penciclovir.- 14. Valaciclovir Update.- 15. Therapeutic Approaches to the Management of Herpes Zoster.- 16. Management of Varicella-Zoster Virus Infections in Children.- 17. Failure of HIV-1 Protease Inhibitors to Fully Suppress Viral Replication: Implications for Salvage Therapy.- 18. New Reverse Transcriptase Inhibitors.- 19. HIV Viral Load Monitoring.- 20. Post-Exposure Prophylaxis for HIV.- 21. Antiretroviral Therapy in Primary HIV.- 22. Initial Treatment for HIV Infection: When, Why, and with What?.- 23. Strategies for Second-Line Antiretroviral Therapy in Adults with HIV Infection.

Reihe/Serie	Advances in Experimental Medicine and Biology ; 458
Zusatzinfo	VIII, 271 p.
Verlagsort	New York, NY
Sprache	englisch
Maße	178 x 254 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Studium ► 1. Studienabschnitt (Vorklinik)
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Naturwissenschaften ► Biologie ► Biochemie
	Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie
ISBN-10	1-4613-7150-3 / 1461371503
ISBN-13	978-1-4613-7150-2 / 9781461371502
Zustand	Neuware